2017 国际专家共识:1级高血压和低至中度心血管风险患者抗高血压药物治疗

2017-05-08 国外心血管相关专家小组(统称) Curr Probl Cardiol. 2017 Jul;42(7):198-225.

高血压是全球疾病负担的主要危险因素,关于1级高血压和低至中度心血管风险患者是否需要进行抗高血压治疗的问题一直没有定论,本文主要针对这些问题达成了专家共识。

中文标题:

2017 国际专家共识:1级高血压和低至中度心血管风险患者抗高血压药物治疗

英文标题:

Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation.

发布日期:

2017-05-08

简要介绍:

高血压是全球疾病负担的主要危险因素,关于1级高血压和低至中度心血管风险患者是否需要进行抗高血压治疗的问题一直没有定论,本文主要针对这些问题达成了专家共识。


拓展指南:高血压相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2017 国际专家共识:1级高血压和低至中度心血管风险患者抗高血压药物治疗)] GetToolGuiderByIdResponse(projectId=1, id=dfd291c001a48eef, title=2017 国际专家共识:1级高血压和低至中度心血管风险患者抗高血压药物治疗, enTitle=Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation., guiderFrom=Curr Probl Cardiol. 2017 Jul;42(7):198-225., authorId=null, author=, summary=高血压是全球疾病负担的主要危险因素,关于1级高血压和低至中度心血管风险患者是否需要进行抗高血压治疗的问题一直没有定论,本文主要针对这些问题达成了专家共识。, cover=, journalId=null, articlesId=null, associationId=738, associationName=国外心血管相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Mon May 08 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=高血压是全球疾病负担的主要危险因素,关于1级高血压和低至中度心血管风险患者是否需要进行抗高血压治疗的问题一直没有定论,本文主要针对这些问题达成了专家共识。 <div><br> </div> 拓展指南:<strong>与<font color=red>高血压</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=6f7211c001a4e6d2" title="2017 TSOC/THS指南:高血压的管理(更新版)" target=_blank>2017 TSOC/THS指南:高血压的管理(更新版)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=e1cb51c001a4489c" title="2017 EHRA/ESC共识文件:高血压和心律失常" target=_blank>2017 EHRA/ESC共识文件:高血压和心律失常</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=17dd91c001a381d2" title="2017 拉丁美洲动脉高血压及相关并发症管理指南" target=_blank>2017 拉丁美洲动脉高血压及相关并发症管理指南</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=e32e81c001a2250b" title="2017 CHEP高血压指南:儿童高血压的诊断,评估,预防和治疗" target=_blank>2017 CHEP高血压指南:儿童高血压的诊断,评估,预防和治疗</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=36df91c001a224fb" title="2017 CHEP高血压指南:成人高血压的诊断,风险评估,预防和治疗" target=_blank>2017 CHEP高血压指南:成人高血压的诊断,风险评估,预防和治疗</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E9%AB%98%E8%A1%80%E5%8E%8B" target=_blank>有关高血压更多指南</a></ul>, tagList=[TagDto(tagId=274, tagName=高血压), TagDto(tagId=266, tagName=心血管), TagDto(tagId=643, tagName=风险), TagDto(tagId=4501, tagName=患者), TagDto(tagId=137, tagName=药物), TagDto(tagId=65, tagName=治疗)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=43, categoryName=冠心病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4088, appHits=323, showAppHits=0, pcHits=2823, showPcHits=1391, likes=135, shares=15, comments=2, approvalStatus=1, publishedTime=Mon Jun 05 15:29:19 CST 2017, publishedTimeString=2017-05-08, pcVisible=1, appVisible=1, editorId=5295982, editor=yanqin, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=yanqin, createdTime=Mon Jun 05 15:29:19 CST 2017, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 22:59:12 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2017 国际专家共识:1级高血压和低至中度心血管风险患者抗高血压药物治疗)])
2017 国际专家共识:1级高血压和低至中度心血管风险患者抗高血压药物治疗
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=207618, encodeId=56e520e6180d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Wed Jun 07 08:36:36 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207273, encodeId=903b20e273a1, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 06 10:35:45 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
    2017-06-07 lou.minghong

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=207618, encodeId=56e520e6180d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Wed Jun 07 08:36:36 CST 2017, time=2017-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207273, encodeId=903b20e273a1, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 06 10:35:45 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
    2017-06-06 Y—xianghai

    学习了新知识

    0